The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

Darron R. Brown, Susanne K. Kjaer, Kristján Sigurdsson, Ole Erik Iversen, Hernandez Avila Mauricio, Cosette M. Wheeler, Gonzalo Perez, Laura A. Koutsky, Eng Hseon Tay, Patricía Garcia, Kevin A. Ault, Suzanne M. Garland, Sepp Leodolter, Sven Eric Olsson, Grace W.K. Tang, Daron Gale Ferris, Jorma Paavonen, Marc Steben, F. Xavier Bosch, Joakim DillnerElmar A. Joura, Robert J. Kurman, Slawomir Majewski, Nubia Muñoz, Evan R. Myers, Luisa L. Villa, Frank J. Taddeo, Christine Roberts, Amha Tadesse, Janine Bryan, Lisa C. Lupinacci, Katherine E.D. Giacoletti, Heather L. Sings, Margaret James, Teresa M. Hesley, Eliav Barra

Research output: Contribution to journalArticlepeer-review

476 Scopus citations

Fingerprint

Dive into the research topics of 'The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years'. Together they form a unique fingerprint.

Medicine & Life Sciences